Nuwellis Inc. (NASDAQ: NUWE) completed a public offering that raised approximately $6 million in gross proceeds, the medical technology company announced.

The offering included 1,903,338 shares of common stock and pre-funded warrants to purchase 18,096,662 shares of common stock. Each unit came with Series C warrants to purchase up to 60 million shares and Series D warrants to purchase up to 20 million shares.

The public offering price was $0.30 per share with accompanying warrants, while pre-funded warrants with accompanying warrants were priced at $0.2999 each. Pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable.

Both Series C and Series D warrants carry an exercise price of $0.30 and will be exercisable for five years following stockholder approval and implementation of a reverse stock split, as required by Nasdaq rules. Series C warrants include a one-time exercise price reset provision tied to potential reverse stock split implementation. Series D warrants feature a zero cash exercise option.

Ladenburg Thalmann & Co. Inc. served as sole book-running manager for the offering.

The securities were offered under a registration statement on Form S-1 that became effective June 4, 2026, and an additional registration statement filed June 5, 2025, according to the company statement.

Nuwellis develops medical technology solutions for patients with cardiorenal conditions, focusing on monitoring, therapy, and clinical decision-making tools for acute and chronic care settings.